Table 1 Baseline demographics and disease characteristics of the patients, and their study disposition
Characteristic | APV 600 mg/RTV 100 mg BID (N = 158) | APV 1200 mg BID (N = 53) |
|---|---|---|
Age, years | ||
Median | 40 | 43 |
Range | 25 – 63 | 29 – 62 |
Gender, No. (%) | ||
Male | 139 (88) | 44 (83) |
Female | 19 (12) | 9 (17) |
Race, No. (%) | ||
Caucasian | 81 (51) | 21 (40) |
Black | 58 (37) | 20 (38) |
Hispanic | 18 (11) | 11 (21) |
Asian | 1 (<1) | 1 (2) |
CDC classification | ||
Caterory A | 74 (47) | 29 (55) |
Category B | 46 (29) | 10 (19) |
Category C | 37 (24) | 14 (26) |
HIV-1 RNA, log10 copies/mL | ||
Mean ± SD | 4.33 ± 0.58 | 4.35 ± 0.66 |
Median (Range) | 4.31 (2.98 – 5.88) | 4.38 (2.74 – 5.81) |
CD4+ cell count, cells/mm3 | ||
Mean ± SD | 307 ± 187 | 327 ± 226 |
Median (Range) | 271 (43 – 948) | 255 (35 – 1054) |
Premature withdrawal | 44 (28) | 17 (32) |
Adverse event | 11 (7) | 4 (8) |
Consent withdrawn | 5 (3) | 2 (4) |
Lost to follow up | 11 (7) | 5 (9) |
Insufficient CD4+ response | 1 (<1) | 0 |
Insufficient viral load response | 4 (3) | 1 (2) |
Protocol-defined virological failure | 2 (1) | 3 (6) |
Other | 10 (6) | 2 (4) |